Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence

Journal of Thoracic Oncology

Volumn 5, Issue 12, 2010, Pages 1894-1904

  Nanjundan, Meera ^a   Byers, Lauren Averett ^b   Carey, Mark S ^b   Siwak, Doris R ^b   Raso, Maria Gabriela ^b   Diao, Lixia ^d   Wang, Jing ^d   Coombes, Kevin R ^d   Roth, Jack A ^b   Mills, Gordon B ^b   Wistuba, Ignacio I ^b   Minna, John D ^c   Heymach, John V ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d University of Texas Southwestern Medical Center ^*

Author keywords

Adhesion; AMPK; NSCLC; Proteomics; Recurrence

Indexed keywords

ADENYLATE KINASE; BETA CATENIN; BIOLOGICAL MARKER; CAVEOLIN 1; CYCLIN B1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PHOSPHOPROTEIN P38; PROTEIN; PROTEIN KINASE B; PROTEIN P70; PROTEIN P70S6K; PROTEIN S6; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CANCER RECURRENCE; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVERSE PHASE PROTEIN LYSATE ARRAY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; VALIDATION PROCESS;

EID: 78650494605     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f2a266     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta, GA: American Cancer Society, 2008.
2. Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005;23:175-183. (Pubitemid 41702636)
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
4. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
5. Chen G, Gharib TG, Huang CC, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002;8:2298-2305. (Pubitemid 34753604)
6. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362:433-439. (Pubitemid 36999706)
7. Kikuchi T, Carbone DP. Proteomics analysis in lung cancer: challenges and opportunities. Respirology 2007;12:22-28. (Pubitemid 44968195)
8. Yanagisawa K, Tomida S, Shimada Y, et al. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst 2007;99:858-867.
9. Sheehan KM, Calvert VS, Kay EW, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005;4: 346-355.
10. Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1: 683-695.
11. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5: 2512-2521. (Pubitemid 44650915)
12. Chu I, Arnaout A, Loiseau S, et al. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest 2007;117:2205-2215. (Pubitemid 47219565)
13. Hennessy BT, Lu Y, Poradosu E, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007;13:7421-7431.
14. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402. (Pubitemid 47539306)
15. Byers LA, Sen B, Saigal B, et al. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009;15:6852-6861.
16. Racine C, Belanger M, Hirabayashi H, et al. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 1999;255:580-586. (Pubitemid 29294841)
17. Ho CC, Kuo SH, Huang PH, et al. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced nonsmall cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer 2008;59:105-110.
18. Kato T, Miyamoto M, Kato K, et al. Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. Cancer Lett 2004;214:121-128. (Pubitemid 39141205)
19. Awaya H, Takeshima Y, Amatya VJ, et al. Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma. Pathol Int 2005;55:14-18. (Pubitemid 40289252)
20. Lu Z, Ghosh S, Wang Z, et al. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003;4: 499-515. (Pubitemid 38050046)
21. Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007;26:5911-5918.
22. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-810. (Pubitemid 47266337)
23. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther 2006;5:430-437.
24. Zhou J, Huang W, Tao R, et al. Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene 2009;28:1993-2002.
25. Jin Q, Feng L, Behrens C, et al. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 2007;67:11630-11639.
26. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909. (Pubitemid 46300206)
27. Deeb G, Wang J, Ramnath N, et al. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol 2004;17:430-439. (Pubitemid 41646598)
28. Zhang Q, Bhola NE, Lui VW, et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 2007;6:1414-1424. (Pubitemid 46712005)
29. Cheng KW, Lu Y, Mills GB. Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol 2005;403:202-215. (Pubitemid 43223113)
30. Hu J, He X, Baggerly KA, et al. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007;23:1986-1994. (Pubitemid 47299840)
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300.
32. Pounds S, Morris SW. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 2003;19:1236-1242. (Pubitemid 36850216)